Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Chimerix (DE:CXF)
FRANKFURT:CXF
Chimerix (CXF) Stock Price & Analysis
0 Followers
CXF Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.81 - €1.42
Previous Close€0.86
Volume200.00
Average Volume (3M)400.00
Market Cap
€79.09M
Enterprise Value-€87.97M
Total Cash (Recent Filing)$180.36M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)N/A
Beta0.95
Next Earnings
Aug 07, 2024EPS Estimate
-€0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding89,210,356
10 Day Avg. Volume20
30 Day Avg. Volume400
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.43
Price to Sales (P/S)2.26
Price to Cash Flow (P/CF)-1.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-2.58
Enterprise Value/Gross Profit-2.64
Enterprise Value/Ebitda0.85
Forecast
1Y Price Target
€7.08Price Target Upside725.93% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Chimerix News
PremiumCompany Announcements
Chimerix Releases Updated Corporate Presentation for Investors
PremiumCompany Announcements
Chimerix Board Changes: Machado Resigns, Kozin AppointedBulls Say, Bears Say
Bulls Say
Clinical Trials ProgressThe ACTION study now has 135 sites across 13 countries, with plans to expand, indicating progress in clinical trials.
Financial HealthThe company has a substantial cash reserve, with management confident in its funding for ongoing clinical trials.
Regulatory MilestonesONC201 has received Fast Track Designation and Rare Pediatric Disease Designation from the FDA, indicating regulatory support and potential for expedited development.
Bears Say
Clinical Trial UpdatesTiming for interim OS data from the phase 3 trial for ONC201 has been delayed.
Financial PerformanceCMRX reported consecutive quarters with net losses, indicating ongoing financial challenges.
Financial PerformanceCMRX reported results with a significant net loss.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.60% Other Institutional Investors
99.40% Public Companies and
Individual Investors
CXF FAQ
What was Chimerix’s price range in the past 12 months?
Chimerix lowest stock price was €0.81 and its highest was €1.42 in the past 12 months.
What is Chimerix’s market cap?
Currently, no data Available
When is Chimerix’s upcoming earnings report date?
Chimerix’s upcoming earnings report date is Aug 07, 2024 which is in 95 days.
How were Chimerix’s earnings last quarter?
Chimerix released its earnings results on May 01, 2024. The company reported -€0.233 earnings per share for the quarter, missing the consensus estimate of -€0.205 by -€0.028.
Is Chimerix overvalued?
According to Wall Street analysts Chimerix’s price is currently Undervalued.
Does Chimerix pay dividends?
Chimerix does not currently pay dividends.
What is Chimerix’s EPS estimate?
Chimerix’s EPS estimate is -€0.22.
How many shares outstanding does Chimerix have?
Currently, no data Available
What happened to Chimerix’s price movement after its last earnings report?
Chimerix reported an EPS of -€0.233 in its last earnings report, missing expectations of -€0.205. Following the earnings report the stock price went down -4.732%.
Which hedge fund is a major shareholder of Chimerix?
Among the largest hedge funds holding Chimerix’s share is RA Capital Management. It holds Chimerix’s shares valued at 8M.
---
Chimerix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.08 (725.93% Upside)
€7.08 (725.93% Upside)
Blogger Sentiment
Bullish
DE:CXF Sentiment 75%
Sector Average 70%
Sector Average 70%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.16%
12-Months-Change
Fundamentals
Return on Equity
-36.50%
Trailing 12-Months
Asset Growth
-23.83%
Trailing 12-Months
Company Description
Chimerix
Chimerix, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.
---
CXF Earnings Call
Q1 2024
0:00 / 0:00
---
CXF Stock 12 Months Forecast
Average Price Target
€7.08
▲(725.93% Upside)
Technical Analysis
Best Analysts Covering CXF
1 Year
1 Year Success Rate
6/22 ratings generated profit
1 Year Average Return
+2.49%
reiterated a buy rating 2 months ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of +2.49% per trade.
---